TITAN PHARMACEUTICALS
Clinical Trials
13
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole
- Conditions
- Parkinson Disease
- Interventions
- First Posted Date
- 2017-08-15
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Titan Pharmaceuticals
- Target Recruit Count
- 6
- Registration Number
- NCT03250117
- Locations
- 🇺🇸
Orlando, Florida, Orlando, Florida, United States
🇺🇸Farmington Hills, Michigan, Farmington Hills, Michigan, United States
🇺🇸Kirkland, Washington, Kirkland, Washington, United States
A Study of Adult Outpatients With Opioid Dependence Transitioned From a Daily SL Buprenorphine to Probuphine® Subdermal Implants
- Conditions
- Opioid Dependence
- Interventions
- Drug: sublingual placebo tabletsDrug: placebo implants
- First Posted Date
- 2014-07-03
- Last Posted Date
- 2019-01-11
- Lead Sponsor
- Titan Pharmaceuticals
- Target Recruit Count
- 177
- Registration Number
- NCT02180659
Re-Treatment Study of Probuphine in Opioid Addiction
- Conditions
- Opioid Dependency
- Interventions
- Drug: Probuphine (buprenorphine implant)
- First Posted Date
- 2010-12-17
- Last Posted Date
- 2018-12-31
- Lead Sponsor
- Titan Pharmaceuticals
- Target Recruit Count
- 85
- Registration Number
- NCT01262261
- Locations
- 🇺🇸
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇺🇸Synergy Clinical Research Center, National City, California, United States
🇺🇸North County Clinical Research, Oceanside, California, United States
A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction
- Conditions
- Opioid Dependency
- Interventions
- First Posted Date
- 2010-05-03
- Last Posted Date
- 2018-12-31
- Lead Sponsor
- Titan Pharmaceuticals
- Target Recruit Count
- 287
- Registration Number
- NCT01114308
- Locations
- 🇺🇸
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇺🇸Synergy Clinical Research Center, National City, California, United States
🇺🇸North County Clinical Research, Oceanside, California, United States
Study of Probuphine in Patients With Opioid Dependence
- Conditions
- Opioid Dependency
- Interventions
- Drug: Probuphine (buprenorphine implant)
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2018-12-31
- Lead Sponsor
- Titan Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT00772785
- Locations
- 🇺🇸
Scientific Clinical Research, Inc., North Miami, Florida, United States
- Prev
- 1
- 2
- 3
- Next
News
Titan Pharmaceuticals Secures $1.6 Million in Strategic Funding Through Two Convertible Preferred Stock Placements
Titan Pharmaceuticals completed two private placements with Blue Harbour Asset Management, raising a total of $1.6 million through convertible preferred stock offerings in April and June 2025.